AB-Biotics seeks partners at Vitafoods Europe to market its cholesterol-lowering and IBS probiotics

 Breaking News
  • Year of Considerable Progress For Dairy Crest Dairy Crest, the UK dairy group, increased revenue by 10% to £456.8 million and adjusted profit before tax increased by 2.8% to £62.3 million for the year ended 31 March 2018, compared with the previous year. Dairy Crest’s Cheese & Functional Ingredients business increased revenue by 8.8% to £277.2 million while revenue at the Butters, [...]...
  • Edrington Unveils the New Home of The Macallan Edrington, the international premium spirits company, has revealed the new distillery and visitor experience for The Macallan brand. The new distillery and visitor experience is located on the stunning Easter Elchies estate in Scotland, which has been home to the leading luxury single malt since 1824. From humble beginnings, the brand has risen to become [...]...
  • Nestlé Strengthens its Research Capabilities in Switzerland Nestlé has announced changes that further strengthen its research and development operations, the largest of any food company worldwide. Nestlé will bring together its two scientific discovery units, the Nestlé Research Center and the Nestlé Institute of Health Sciences, to build one impactful organization, Nestlé Research. The combination of two world-renowned research facilities with highly [...]...
  • Algaia Receives €4 Million Boost Algaia, will accelerate development and install a new specialty seaweed extract production unit at its Lannilis (Brittany-France) manufacturing facility dedicated to specialty algae extracts. The company’s main shareholder, Maabarot Products, has injected an additional €4 million in equity to support further expansion of the production facility and innovation center located in Saint-Lo (Normandy-France). Algaia works with local [...]...
  • Smarter Factories – Safer Working In food produce environments and packhouses, the benefits of automation when it comes to workforce health and safety are uncontended. From eliminating arduous and repetitive tasks to working uninterrupted within inhospitable chilled settings, robots are most certainly the future. Case loading specialist Brillopak and industrial automation pioneer Omron explore how smart robots, hardware and software can [...]...

AB-Biotics seeks partners at Vitafoods Europe to market its cholesterol-lowering and IBS probiotics

May 21
11:06 2012
  •  The Spanish biotech company looks for pharma or food companies interested in selling these IP-protected and clinically tested nutraceuticals, AB-LIFE and I3.1, in Europe and around the world

Barcelona (Spain).- The Spanish biotech company AB-Biotics presents these days at Vitafoods Europe, in Geneva, its  new probiotics AB-LIFE and I3.1, focused on the prevention and treatment of cholesterol and irritable bowel syndrome, respectively. The company wants to contact pharma or food companies interested in licensing these functional ingredients in the European. market and / or worldwide.

This important meeting is held in Geneva from 22th to 24th May. AB-Biotics wants to take advantage of this international showcase to look for licensors for two revolutionary probiotics. “The applications of AB-LIFE and I3.1 for the industry are very diverse, so in recent months several companies from different countries have already expressed interest in a possible license agreement”, said Sergi Audivert and Miguel Angel Bonachera, CEOs of AB-Biotics.


AB-LIFE: the first probiotic therapy in preventing cardiovascular disease

AB-BIOTICS is looking for pharmaceutical companies interested in licensing AB-LIFE in new markets. AB-LIFE is a nutritional ingredient which reduces cholesterol levels by 14%, according to clinical studies performed by Hospital Puerta del Hierro inMadrid. In addition to its greater efficacy, this new ingredient has another important difference in comparison with other solutions in the market: it not only reduces the levels of cholesterol ingested in the diet, but also blood cholesterol levels, leading to increased effectiveness in a larger number of people. 

With AB-LIFE, the Spanish company AB-BIOTICS has opened the door to probiotic therapy in preventing cardiovascular disease. As well as its possible use in the form of capsules, AB-LIFE can be added to foods with no thermal treatment, such as dairy products, or to drinks or juices using encapsulation techniques. AB-Biotics has already signed agreement agreements with different companies to distribute AB-LIFE in Southeast Europe, particularly in the markets of Slovenia, Croatia, Bosnia-Herzegovina, Serbia, Montenegro, Macedonia and Albania; and also Spain and Brazil.


I3.1: a better quality of life for IBS patients

Irritable Bowel Syndrome (IBS) is considered to be the most common gastrointestinal disorder. Its prevalence in western world is estimated to be 10-15% of the adult population. Current treatments for IBS have limited efficacy and severe side effects have been reported in recently approved drugs. AB-BIOTICS has developed I3.1, the first probiotic formula which produces a global improvement of quality of life in IBS patients.

I3.1 consists of a combination of three lactic acid bacteria, more precisely two Lactobacilli and one Pediococcus. Strains in I3.1 formula are able to produce high amounts of short chain fatty acids, especially, butyric acid. SCFAs are readily absorbed by intestinal mucosa and are known to stimulate serotonin release, which modulates both gut motility and sensation. Therefore, in situ production of SCFAs by strains of the I3.1 formula is useful to modulate gut motility and reduce visceral pain. Moreover, I.31 has displayed significant anti-inflammatory activity in two different animal models of gut inflammation, reducing both external symptoms of IBS and molecular markers. Also, 3.1 displays a significant inhibitory activity against many pathogenic bacterial strains, while allowing the growth of common commensal bacteria of the human gastrointestinal flora. Clinical trial has confirmed that I3.1 makes a positive improvement in health-related quality of life of IBS patients, reducing gastrointestinal discomfort and pain. “AB-BIOTICS is looking for pharmaceutical companies interested in licensing I3.1 in different markets –said Sergi Audivert and Miquel Àngel Bonachera, CEOs of AB-BIOTICS-. The product can be dosed both in capsules, tablets and sachets, with a product stability of at least 2 years”.



AB-BIOTICS is a Spanish biotechnology company focused on research, development, protection and distribution of its own exclusive biotechnological solutions.  The company’s mission is to improve the health and wellbeing of people. The company has an innovative philosophy and its own know-how that allows it to develop avant-garde products with high added value for the market.

 Since 2010, ABBIOTICS is listed in the Alternative Investment Market (MAB, in Spanish). The company has just started its international expansion plan, in order to reinforce their commercial activity and be present in high-potential countries like theUnited States, theUnited Kingdom,Germany,France,Turkey,Mexico andBrazil.


More information: http://www.ab-biotics.com/
Nuria Peláez – Communications officer
0034 654 352 541

About Author



Related Articles

Food & Drink Business Conference & Exhibition 2016

Upcoming Events

  • June 1, 2018Gluten Free Expo Slovakia
  • June 3, 2018Vinoble
  • June 4, 20188th WSO World Congress on Stevia Tasteful 2018
  • June 17, 2018The Excellence of Italian Food and Wine (Bellavita Expo)
AEC v1.0.4

find food jobs

The Magazine

F&D Business Preferred Suppliers

New Subscriber

Subscribe Here